on Mainz BioMed N.V.
Mainz Biomed Partners with Liquid Biosciences to Enhance Pancreatic Cancer Detection
Mainz Biomed N.V., a molecular genetics diagnostic company, has announced an expanded collaboration with Liquid Biosciences to enhance biomarker selection for PancAlert, its next-generation pancreatic cancer detection test. The collaboration leverages Liquid Biosciences' proprietary AI platform, EMERGE.
The initial phase evaluated biomarkers from a program supported by the German Federal Ministry for Education and Research. Promising results led to plans for further collaboration. This next phase will incorporate microbiome biomarkers and extend the AI algorithm, aiming to complete analysis by Q4 2024.
Guido Baechler, CEO of Mainz Biomed, emphasized the potential impact of this collaboration in developing early-stage detection tests for pancreatic cancer, highlighting the high mortality rate and low survival rate associated with late detection of this disease.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news